Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on the bottom line, with a GAAP EPS of -$0.62 vs. -$0.57 expected, and a normalized net loss of $5.31M exceeding the anticipated $4.92M. Operating expenses surged to $6.64M, primarily driven by a 176% YoY increase in R&D as the company accelerated rolling NDA submissions for ALXN1840. Despite the earnings miss, liquidity remains robust with $134.3M in cash and investments, supporting operations through late 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Monopar Therapeutics(MNPR) the EBIT is -6.645 M (-105.4%), Miss estimate;the EPS is -0.62 (-77.14%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B105.44%
-0.01B74.95%
-0.00B30.49%
EPSMiss expectations
-0.6277.14%
-0.570963.12%
-0.049114.02%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf